A compound represented by Formula (1) or (3).

##STR00001##

wherein R.sup.1 and R.sup.2 are each independently a hydrogen atom; a C1-6 alkyl group optionally having one or more substituents selected from the group consisting of a carboxy group and —OR.sup.5; a C2-6 alkyl group having one or more substituents selected from the group consisting of —NR.sup.6R.sup.7 and —N.sup.+R.sup.9R.sup.10R.sup.11; or —(CH.sub.2CH.sub.2O).sub.nR.sup.8;

##STR00002##

wherein R.sup.4 is a C1-6 alkyl group having one or more substituents selected from the group consisting of a carboxy group and —OR.sup.5; a C2-6 alkyl group having one or more substituents selected from the group consisting of —NR.sup.6R.sup.7 and —N.sup.+R.sup.9R.sup.10R.sup.11, or —(CH.sub.2CH.sub.2O).sub.nR.sup.8;
wherein R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 are each independently a hydrogen atom or a C1-3 alkyl group; and n is an integer of 2 to 5.

The present invention relates to a process for drying crystalline sugammadex to meet solvent specifications that is independent of API crystallinity or crystalline form generated. It further relates to use of sugammadex in the reversal of neuromuscular blockade induced by recuronium bromide or by vecuronium bromide in adults undergoing surgery.

The invention relates to injectable pharmaceutical compositions, methods of use and formulation, wherein the compositions comprise: one or more water soluble complexes, each complex comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug; at least one preservative; and at least one co-solvent. The compositions are effectively preserved in accordance with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria as it applies to parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing, satisfying the criteria for Category 1 (injectable) products.

The present disclosure relates to charge-bearing polymeric materials and methods of their use for purifying fluid samples from micropollutants, such as anionic micropollutants.

Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Provided are a macromolecular material that exhibits high toughness and self-healing properties, and that can be produced by a simple process, as well as a method for producing the material. The macromolecular material contains a crosslinked polymer crosslinked by the interaction between a host group and a guest group. The crosslinked polymer contains a repeating structural unit represented by the following formula (1a) and a repeating structural unit represented by the following formula (2a). ##STR00001##

The present invention relates to compositions comprising fractionated alkylated cyclodextrin compositions having a single degree of substitution, and processes for preparing and using the same.

SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

The present disclosure is related to processes for efficient large-scale preparation of alkylated cyclodextrins. The processes of the present disclosure provide high purity alkylated cyclodextrins with high purity and low levels of chloride while improving efficiency, increasing batch size, and reducing total process time.